Comparison

Human PD-1 Protein, His Tag (Nanoparticle) European Partner

Item no. PD1-H52H2-500ug
Manufacturer ACROBiosystems
Amount 500 ug
Quantity options 100 ug 1 mg 500 ug
Category
Type Proteins Recombinant
Format Solid
Specific against Human (Homo sapiens)
Host HEK293
Conjugate/Tag Unconjugated, HIS
Purity 90%
NCBI NP_005009.2
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Shipping Condition Room temperature
Available
Manufacturer - Category
Protein / Immune Checkpoint Proteins
Manufacturer - Conjugate / Tag
C-10xHis, Unconjugated
Shipping Temperature
RT
Storage Conditions
-20°C
Molecular Weight
47.1 kDa
Manufacturer - Format
Powder
Description
Human PD-1 Protein, His Tag (PD1-H52H2) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
Molecule
PD-1
Exp Region
Leu 25 - Gln 167
Characteristics
Human PD-1 Protein, His Tag is designed and expressed as nanoparticles of approximately 25 nm diameter by displaying PD-1 ECD in native conformation. The nanoparticles each was coated with an average of 180 PD-1 ECD.

The nanoparticle technology allows directional and high-density display of human PD-1 on the surface of nanoparticles, thus greatly enhances the immune response in vivo to otherwise poorly immunogenic epitopes.

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 47.1 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
0.5 EU per μg
Buffer
PBS with glycine and sodium citrate, pH 8.0
Stability
● -20°C to -70°C for 12 months in lyophilized state;
● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant
trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?